Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.52 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.52 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.52 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4222907 | 1.00 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL14384982 | 0.95 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL14385610 | 0.91 | PIK3CD (0.57) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL21301610 | 0.90 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL4233326 | 0.89 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL14385621 | 0.87 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL14385586 | 0.85 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL4228117 | 0.85 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL4228121 | 0.85 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL14385580 | 0.85 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| EP-3530290-A1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-1964577-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| EP-1964577-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| CN-101171039-B | Enzyme and receptor modulation | CHROMA THERAPEUTICS LTD | 2013-01-23 | — | — | CN | disclosed |
| US-20090215800-A1 | Enzyme and Receptor Modulation | CHROMA THERAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215800-A1 | Enzyme and Receptor Modulation | CHROMA THERAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215800-A1 | Enzyme and Receptor Modulation | CHROMA THERAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| EP-1964578-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964577-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964577-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| CN-101171039-A | Enzyme and receptor modulation | CHROMA THERAPEUTICS LTD (GB) | 2008-04-30 | — | — | CN | disclosed |
| EP-1877098-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117567-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | PIK3CD 2423/4885PIK3CG 2786/4885PIK3CA 2707/4885 |
| US-20090215800-A1 | Enzyme and Receptor Modulation | CES1, HCAR1, DNPEP | PIK3CD 2423/4885PIK3CG 2786/4885PIK3CA 2707/4885 |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | PIK3CD 2423/4885PIK3CG 2786/4885PIK3CA 2707/4885 |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | PIK3CD 2423/4885PIK3CG 2786/4885PIK3CA 2707/4885 |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | PIK3CD 2423/4885PIK3CG 2786/4885PIK3CA 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.